Biogen, Capsigen Launch Up-to-$1.3B AAV Capsid Collaboration

Biogen, Capsigen Launch Up-to-$1.3B AAV Capsid Collaboration
May 11, 2021
Share
Biogen will partner with Capsigen to engineer novel adeno-associated virus (AAV) capsids for gene therapies designed to treat CNS and neuromuscular disorders, through a strategic research collaboration that could generate more than $1.3 billion for Capsigen.
The companies said they will create and identify novel AAV capsids tailored to meet disease-specific transduction profiles through their collaboration, designed to combine Capsigen’s Transcription-Dependent Directed Evolution (TRADE™) platform and associated technologies with Biogen’s discovery, development, manufacturing, and commercialization capabilities.
Capsigen’s technology is designed to produce dose optimized, fit for purpose vectors that may have applicability across Biogen’s gene therapy pipeline.

Related Keywords

Georgem Church ,Dyno Capsidmap ,John Bial ,Alfred Sandrock Jr ,Harvard Medical School ,Canbridge Pharmaceuticals ,Novartis ,Transcription Dependent Directed Evolution ,Dyno Therapeutics ,Sarepta Therapeutics ,Spark Therapeutics ,Logicbio Therapeutics ,Munich Based Sirion Biotech ,Molecular Therapeutics ,ஆல்ஃபிரட் சாண்ட்ராக் ஜூனியர் ,ஹார்வர்ட் மருத்துவ பள்ளி ,கான்பிரிட்ஜ் மருந்துகள் ,நோவர்த்திச் ,டைனோ சிகிச்சை ,சாறெப்டா சிகிச்சை ,தீப்பொறி சிகிச்சை ,மூலக்கூறு சிகிச்சை ,